TUCSON, Ariz.--(BUSINESS WIRE)--Protein Technologies, a leader in the field of peptide synthesis instrumentation, today announces that researchers at the University of Utah have developed an innovative use of peptide mimics as drug target surrogates to develop new treatments for Ebola. A large collaborative team led by Debra Eckert, Ph.D., research assistant professor of biochemistry, and Michael S. Kay, M.D., Ph.D., professor of biochemistry, have identified a peptide sequence that is conserved in all known species of Ebola and is thought to control the virus’ entry into human cells. This peptide mimic can be used as a target to identify new drug treatments to control the Ebola virus.
“The use of peptide mimics as drug targets played a key role in the development of treatments for HIV, and we believe this approach can be applied to the treatment of Ebola,” said Dr. Kay. “The Prelude™ system from Protein Technologies enabled us to quickly design and optimize the synthesis of the peptide mimics of the ebolavirus N-trimer.”
Help employers find you! Check out all the jobs and post your resume.
